Drug Trial Radar · NCT05504057
Antihistamines, Amantadine and Evolution of COVID-19
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140,660
Planned (sponsor's estimate)
Start
Mar 1, 2020
Primary completion
Jan 19, 2025
Study completion Feb 24, 2028
Sponsor
- Lead sponsor
- Consorci Sanitari de TerrassaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Institut Català de la Salut
- First posted
- Aug 17, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.
Conditions
- COVID-19
Interventions
AntihistamineDrug
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines
AmantadineDrug
Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hospital Admissions.Time frame: from march 2020.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital de Terrassa
Terrassa, Barcelona, Spain · Recruiting
Hospital of Terrassa
Terrassa, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.